Please login to the form below

Not currently logged in

EFPIA's Richard Torbett to move to the ABPI

Will take up commercial role at UK pharma bodyat the end of the month

ABPI Richard TorbettThe Association of the British Pharmaceutical Industry (ABPI) has appointed Richard Torbett as executive director - commercial UK.

He will take up the role at the end of this month, moving from European pharma trade association EFPIA, where he was chief economist and director of strategy.

Prior to this Torbett spent six years at Pfizer, where he was a senior director and head of international affairs.

In his new role Torbett will be responsible for heading up the ABPI's commercial strategy and leading its UK commercial team, and will report to the ABPI's chief executive.

Alison Clough, acting CEO, said: “With his wealth of knowledge and expertise, Richard will be very well placed to direct the ABPI's commercial strategy and to lead the UK commercial team.

“His experience in both government and the pharmaceutical industry will prove invaluable when addressing the issues of access and use of new medicines in the NHS and in leading discussions with the Department of Health around the PPRS.”

At the ABPI Torbett will focus on pricing, the Pharmaceutical Price Regulation Scheme (PPRS), health technology assessments (HTA) and value assessment, as well as market access in the UK.

22nd July 2015

From: Regulatory



Featured jobs

Subscribe to our email news alerts


Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...